Possibility of blood test parameters usage in the evaluation of COVID-19 patients’ inflammatory status

Cover Page

Cite item

Full Text

Abstract

Background: C-reactive protein (CRP) is a key laboratory biomarker for anti-inflammatory treatment initiation. Unfortunately, biochemical blood analyzers are not always easily accessible in medical institutions located far from major regional health facilities.

Aim: To develop an approach for inflammatory status estimation based on blood test results in patients with COVID-19 in cases with limited laboratory equipment availability.

Methods: The present retrospective study included 423 patients (male 54.6%; female 45.4%; mean age 59.1 years) receiving hospital treatment due to COVID-19 in Medical Research and Educational Center of Lomonosov Moscow State University from April 21st to June 13th 2020. All patients donated blood for full biochemistry and hematology testing and underwent chest computer tomography (CT).

Results: CRP levels (>60 mg/L) qualitative estimation model was developed based on hematologic test results. It included erythrocyte sedimentation rate and neutrophils to lymphocytes ratio. According to the results of Receiver Operating Characteristic (ROC) analysis present model was characterized by sensitivity of 70.2%, specificity of 74.6%, and area under the ROC-curve of 0.781. Comparison of key clinical parameters reflecting COVID-19 severity, such as length of hospitalization, lung damage at CT (hospital admission and discharge), revealed statistically significant difference between groups with routinely measured CRP levels ≤60 mg/L and >60 mg/L for all the above-mentioned parameters (p <0.05). These differences remained significant when measured CRP levels were substituted with estimated CRP values, indicating interchangeability of these approaches to CRP levels determination, regarding clinically important parameters.

Conclusions: Presented model for inflammatory status estimation based on hematologic test results might be used to overcome clinical challenges in cases with limited laboratory equipment availability.

About the authors

Ludmila A. Nekrasova

Specialized Research and Educational Center of Novosibirsk State University

Email: l.nekrasova@nsu.ru
ORCID iD: 0000-0002-5161-8666
SPIN-code: 5609-3840
Russian Federation, Novosibirsk

Mark Jain

Lomonosov Moscow State University

Author for correspondence.
Email: jain-mark@outlook.com
ORCID iD: 0000-0002-6594-8113
SPIN-code: 3783-4441

junior researcher of the Laboratory Diagnostics Department

Russian Federation, 27/10, Lomonosovsky prospect, Moscow, 119234

Nikita S. Gubenko

Lomonosov Moscow State University

Email: gubenkons@icloud.com
ORCID iD: 0000-0001-5723-4367

student of the Faculty of Fundamental Medicine

Russian Federation, Moscow

Anton A. Budko

Lomonosov Moscow State University

Email: anton-budko@mail.ru
ORCID iD: 0000-0002-7362-176X

post-graduate student of the Faculty of Fundamental Medicine

Russian Federation, Moscow

Larisa M. Samokhodskaya

Lomonosov Moscow State University

Email: slm@fbm.msu.ru
ORCID iD: 0000-0001-6734-3989
SPIN-code: 5404-6202

MD, PhD, Associate Professor, head of the Laboratory Diagnostics Department

Russian Federation, Moscow

Iana A. Orlova

Lomonosov Moscow State University

Email: 5163002@bk.ru
ORCID iD: 0000-0002-8160-5612
SPIN-code: 3153-8373

MD, Dr. Sci. (Med.), PhD, Assistant Professor, head of the age-related diseases department

Russian Federation, Moscow

Armais A. Kamalov

Lomonosov Moscow State University

Email: priemnaya@mc.msu.ru
ORCID iD: 0000-0003-4251-7545
SPIN-code: 6609-5468

MD, Dr. Sci. (Med.), Professor, academician of the Russian Academy of Sciences

Russian Federation, Moscow

References

  1. Who.int [Internet]. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 [updated 2021, August 14; cited 2021, August 14]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
  2. Worldometers.info [Internet]. American Library Association. COVID-19 Coronavirus Pandemic [updated 2021, August 14; cited 2021, August 14]. Available from: https://www.worldometers.info/coronavirus/.
  3. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi: 10.1093/cid/ciaa248
  4. Ragab D, Eldin HS, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446
  5. Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta. 2020;509:91–94. doi: 10.1016/j.cca.2020.06.013
  6. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504. doi: 10.1016/j.intimp.2020.106504
  7. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020). Минздрав России; 2020.
  8. Mareev VY, Orlova YA, Pavlikova EP, et al. Steroid pulse-therapy in patients with coronAvirus Pneumonia (COVID-19), sYstemic inFlammation and Risk of vEnous thRombosis and thromboembolism (WAYFARER Study) [In English, Russian]. Kardiologiia. 2020;60(6):15–29. doi: 10.18087/cardio.2020.6.N1226
  9. Yang P, Ding Y, Xu Z, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. MedRxiv. 2020. doi: 10.1101/2020.02.28.20028068
  10. Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395:e35. doi: 10.1016/S0140-6736(20)30305-6
  11. Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020. doi: 10.1101/2020.02.10.20021832
  12. Nhc.gov.cn [Internet]. Disease Control and Prevention Bureau of China. Interpretation of New Coronavirus Pneumonia Prevention and Control Plan (Fifth Edition) [updated 2021, August 14; cited 2021, August 14]. Available from: http://www.nhc.gov.cn/jkj/s3578/202002/dc7f3a7326e249c0bad0155960094b0b.shtml.
  13. Henry BM, de Oliveira MH, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028. doi: 10.1515/cclm-2020-0369
  14. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatric Pulmonology. 2020;55:1169–1174. doi: 10.1002/ppul.24718
  15. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7
  16. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi: 10.1016/S2213-2600(20)30079-5
  17. Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–399. doi: 10.1080/10408363.2020.1770685
  18. Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging. 2020;12(7):6037–6048. doi: 10.18632/aging.102999
  19. Lu J, Sun PD. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. J Biol Chem. 2020;295(52):18579. doi: 10.1074/jbc.ra120.015303
  20. Khanna K, Raymond W, Charbit AR, et al. Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies. BioRxiv. 2020. doi: 10.1101/2020.12.08.415505
  21. Smilowitz NR, Kunichoff D, Farshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270–2279. doi: 10.1093/eurheartj/ehaa1103
  22. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–334. doi: 10.1016/j.medmal.2020.03.007
  23. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virology. 2020;92(7):856–862. doi: 10.1002/jmv.25871

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. ROC-curve for the prediction of C-reactive protein levels more than 60 mg/L. Note: Нейт. — neutrophils; Н/Л — ratio of neutrophil and lymphocyte levels; СОЭ — erythrocyte sedimentation rate; КСРБ60 — coefficient of excess of C-reactive protein level 60 mg/l.

Download (950KB)
3. Fig. 2. Lung damage according to the results of computer tomography depending on C-reactive protein levels: a — data acquired at hospital admission; б — data acquired at hospital discharge. Note: КТ — computed tomography; СРБ — C-reactive protein (laboratory analysis); рСРБ — C-reactive protein (calculation according to the developed model).

Download (1MB)
4. Fig. 3. Step-by-step algorithm for C-reactive protein level estimation. Note: СРБ — C-reactive protein; Н/Л — ratio of neutrophil and lymphocyte levels; СОЭ — erythrocyte sedimentation rate.

Download (901KB)

Copyright (c) 2022 Nekrasova L.A., Jain M., Gubenko N.S., Budko A.A., Samokhodskaya L.M., Orlova I.A., Kamalov A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies